<DOC>
	<DOCNO>NCT02362516</DOCNO>
	<brief_summary>To assess exposure BI 425809 cerebrospinal fluid relative plasma well safety tolerability , evaluate effect different dos BI 425809 biomarkers level cerebrospinal fluid .</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamic Effect Different Multiple Oral Doses BI 425809</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : Healthy male accord investigator 's assessment , base complete medical history include physical examination , vital sign ( blood pressure ( BP ) , puls rate ( PR ) ) , 12lead electrocardiogram ( ECG ) , clinical laboratory test Age 18 55 year ( incl . ) Body Mass Index ( BMI ) 18.5 29.9 kg/m2 ( incl . ) Signed date write informed consent prior admission study accordance good clinical practice ( GCP ) local legislation Exclusion criterion : Any find medical examination ( include blood pressure ( BP ) , puls rate ( PR ) electrocardiogram ( ECG ) ) deviate normal judge clinically relevant investigator Repeated measurement systolic blood pressure outside range consider clinical relevant investigator Any laboratory value outside reference range investigator considers clinical relevance Any evidence concomitant disease judge clinically relevant investigator Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Surgery gastrointestinal tract could interfere kinetics trial medication Diseases central nervous system ( include limit kind seizure stroke ) , relevant neurological psychiatric disorder Further exclusion criterion may apply</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>